Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Insmed Incorporated | Brensocatib - (WILLOW) | Bronchiectasis | Phase 2 | Ongoing | Oral | Respiratory |
| Insmed Incorporated | ARIKAYCE - (ENCORE) | Newly Diagnosed or Recurrent MAC Lung Disease | Phase 3 | Enrollment Conclusion | Inhalation | Respiratory |
| Insmed Incorporated | Brensocatib - (CEDAR) | Hidradenitis suppurativa (HS) | Phase 2 | Enrollment Initiation | oral | Immunology: Anti-TNF |
| Insmed Incorporated | Treprostinil palmitil inhalation powder (TPIP) | Proliferative vitreoretinopathy (PVR) | Phase 2b | Trial Planned | Inhalation | Opthalmic |
| Insmed Incorporated | Treprostinil palmitil inhalation powder (TPIP) | Progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) | Phase 3 | Trial Planned | Inhalation | Respiratory |
| Insmed Incorporated | Treprostinil Palmitil Inhalation Powder (TPIP) | Pulmonary arterial hypertension (PAH) | Phase 2b | Data Released | Inhalation | Cardiology |
| Instil Bio Inc. | ITIL-168 - (DELTA-1) | Melanoma | Phase 2 | Trial Discontinued | intravenous | Oncology |
| IntelGenx Technologies Corp | Montelukast VersaFilm - (MONTPARK) | Parkinson's Disease (PD) | Phase 2 | Enrollment Initiation | Buccal | Neurology |
